(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.34%) $78.75
(0.27%) $2.20
(0.16%) $2 335.00
(0.28%) $27.69
(0.27%) $967.50
(0.02%) $0.928
(0.02%) $10.83
(0.01%) $0.796
(-0.11%) $91.35
4 days till quarter result
(bmo 2024-05-10)
Expected move: +/- 14.10%
-3.36% $ 1.150
@ $1.280
Wydano: 14 vas. 2024 @ 16:35
Zwrot: -10.16%
Poprzedni sygnał: vas. 13 - 16:30
Poprzedni sygnał:
Zwrot: 11.20 %
Live Chart Being Loaded With Signals
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom...
Stats | |
---|---|
Dzisiejszy wolumen | 839 351 |
Średni wolumen | 1.54M |
Kapitalizacja rynkowa | 261.24M |
EPS | $0 ( 2024-03-04 ) |
Następna data zysków | ( $-0.160 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.13 |
ATR14 | $0.00500 (0.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Ecor1 Capital, Llc | Buy | 0 | Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 5 088 864 | Option to purchase Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 1 130 832 | Option to purchase Ordinary Shares |
2024-01-17 | Rawcliffe Adrian | Sell | 30 080 | American Depositary Shares representing Ordinary Shares |
2024-01-16 | Rawcliffe Adrian | Sell | 9 304 | American Depositary Shares representing Ordinary Shares |
INSIDER POWER |
---|
96.15 |
Last 96 transactions |
Buy: 71 750 188 | Sell: 1 254 319 |
Wolumen Korelacja
Adaptimmune Therapeutics Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ASLN | 0.967 |
FBRX | 0.966 |
CLPT | 0.966 |
AGRX | 0.964 |
VLCN | 0.963 |
SCPH | 0.961 |
SOFO | 0.961 |
TELA | 0.959 |
ESTA | 0.958 |
OMCL | 0.957 |
10 Najbardziej negatywne korelacje | |
---|---|
ADV | -0.976 |
MLAI | -0.97 |
RCMT | -0.969 |
NVSA | -0.967 |
SVRA | -0.965 |
MPRA | -0.965 |
STCN | -0.964 |
SCOB | -0.964 |
KAII | -0.964 |
BTWN | -0.963 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Adaptimmune Therapeutics Korelacja - Waluta/Towar
Adaptimmune Therapeutics Finanse
Annual | 2023 |
Przychody: | $60.51M |
Zysk brutto: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2023 |
Przychody: | $60.51M |
Zysk brutto: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2022 |
Przychody: | $27.15M |
Zysk brutto: | $-100.58M (-370.48 %) |
EPS: | $-1.030 |
FY | 2021 |
Przychody: | $6.15M |
Zysk brutto: | $6.15M (100.00 %) |
EPS: | $-1.020 |
Financial Reports:
No articles found.
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej